Thursday, 2 May 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 02 May 2024
Listen to this story 
News

GLP-1 drugs cleared of risk

Posted 16 April 2024 AM

Europe's medicines regulator, the EMA, has found no causal association between GLP-1 receptor agonists and the risk of suicidal thoughts and actions after a review which lasted close to nine months.

The investigation, triggered by the Icelandic medicines agency, originally looked at three Novo Nordisk's Saxenda and semaglutide products Ozempic, and Wegovy but was quickly extended to include Eli Lilly's Trulicity, AstraZeneca's Byetta.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (26)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (9)

Other (22)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.